Full Title
Phase 2 Study of the Combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter’s TransformationPurpose
When people have Richter’s transformation, their chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) changes into a more aggressive disease. Researchers are assessing a new drug combination for people with Richter’s transformation that came back or keeps growing after treatment.
If you take part in this study, you will get nivolumab immunotherapy, ibrutinib, and lisocabtagene maraleucel (liso-cel). Liso-cel is a CAR T-cell therapy made from your own white blood cells that have been modified in a lab.
Nivolumab boosts the power of the immune system to find and kill cancer cells. Ibrutinib blocks proteins that cancer cells need to survive and grow. It may also improve the ability of CAR T cells to fight the cancer. It is taken orally (by mouth) and the other treatments in this study are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have Richter’s transformation that came back or is getting worse after treatment.
- Have recovered from the serious side effects of prior therapies before getting the study treatment.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Alexander Boardman’s office at 646-608-2091.